Zevra Therapeutics, Inc. ZVRA
11.17 USD +0.91 (+8.87%)
At closeNov 4, 2026, 4:39 PM EST
11.17 0.00 0.00%
After hours · Nov 4, 4:39 PM ET
10.53 Day range 11.19
8.01 52-week range 15.04
- YTD
- +24.67%
- 1 year
- +14.10%
News
seekingalpha.com Zevra Therapeutics, Inc. (ZVRA) Q3 2026 Earnings Call Transcript Zevra Therapeutics, Inc. (ZVRA) Q3 2026 Earnings Call Transcript
zacks.com Zevra Therapeutics (ZVRA) Q3 Earnings and Revenues Beat Estimates Zevra Therapeutics (ZVRA) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to a loss of $0.01 per share a year ago.
marketbeat.com Zevra Therapeutics Q3 Earnings Call Highlights Zevra Therapeutics NASDAQ: ZVRA reported third-quarter 2026 net revenue of $37.8 million, up 45% from $26.1 million a year earlier, driven primarily by U.S. sales of MIPLYFFA for Niemann-Pick disease…
benzinga.com Zevra Therapeutics Q3 2026 Earnings Call Transcript Zevra Therapeutics (NASDAQ:ZVRA) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Zevra Therapeutics Q3 EPS $0.26 Beats $0.16 Estimate, Sales $37.756M Beat $37.079M Estimate Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.16 by 62.5 percent. This is a 2700 percent increase over losses of…
globenewswire.com Zevra Reports Third Quarter 2026 Financial Results and Corporate Update $37.8 million net revenue for Q3 2026 , driven by $34.0 million in revenue from MIPLYFFA
globenewswire.com Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call BOSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living…
seekingalpha.com Zevra Therapeutics: Cash Plus A Drug Priced Below Its Rival's Deal Zevra Therapeutics is rated Buy, with a fair value of $13.38 per share, 28.7% above current levels. ZVRA's valuation is anchored by $260.2M in cash and a drug business priced at less than a fifth of…
benzinga.com Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sjögren’s trial was halted for futility; others also slid.
seekingalpha.com Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing Factor Zevra Therapeutics is a buy-rated, single-asset rare disease play with Miplyffa driving strong U.S. growth and early profitability. 2Q26 net revenue reached $39.7M, up 53% YoY, with Miplyffa…
seekingalpha.com Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
benzinga.com MongoDB, Credo Technology Group And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session US stock futures lower, MongoDB shares down 13.4% in pre-market trading after earnings beat estimates. Other stocks also declining in pre-market.
globenewswire.com Zevra Therapeutics to Present at Upcoming Investor Conferences BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people…
benzinga.com Zevra Therapeutics To Present Two Posters Featuring Long-Term Real-World Data On MIPLYFFA For Treatment Of Niemann-Pick Disease Type C At SSIEM Annual Symposium Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced the…
globenewswire.com Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium BOSTON, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living…
globenewswire.com Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BOSTON, Mass., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people…
benzinga.com HC Wainwright & Co. Reiterates Buy on Zevra Therapeutics, Maintains $26 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and maintains $26 price target.
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised…
defenseworld.net Dimensional Fund Advisors LP Acquires 400,336 Shares of Zevra Therapeutics, Inc. $ZVRA Dimensional Fund Advisors LP boosted its holdings in Zevra Therapeutics, Inc. (NASDAQ: ZVRA) by 259.2% in the first quarter, according to the company in its most recent 13F filing with the SEC. The…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (“Zevra” or the “Company”) (NASDAQ: ZVRA). Such investors are…
benzinga.com Guggenheim Maintains Buy on Zevra Therapeutics, Lowers Price Target to $23 Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $24 to $23.
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised…- benzinga.com Citizens Maintains Market Outperform on Zevra Therapeutics, Raises Price Target to $28 Citizens analyst Jason N. Butler maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Market Outperform and raises the price target from $25 to $28.
marketbeat.com Zevra Therapeutics Q2 Earnings Call Highlights Zevra Therapeutics NASDAQ: ZVRA reported second-quarter 2026 net revenue of $39.7 million, up 53% from $25.9 million a year earlier, driven primarily by U.S. sales of its Niemann-Pick disease type C…
seekingalpha.com Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript
zacks.com Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates Zevra Therapeutics (ZVRA) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $1.21 per share a year ago.
benzinga.com Zevra Therapeutics Says Expects To Continue Engagement With The U.S. FDA In The H2 2026 To Explore Pathways To Accelerate Clinical Development Enrolled four patients in the event-driven Phase 3 DiSCOVER trial of celiprolol for the treatment of Vascular Ehlers-Danlos Syndrome during Q2 2026, bringing the total number of enrolled patients to…
benzinga.com UPDATE: Zevra Therapeutics Q2 Adj. EPS $0.25 Beats $0.14 Estimate, Sales $39.663M Beat $33.572M Estimate Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.14 by 78.57 percent. This is a 79.84 percent decrease over earnings of…
benzinga.com Zevra Therapeutics Q2 EPS $0.14 Beats $0.11 Estimate, Sales $39.663M Beat $33.881M Estimate Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.11 by 27.27 percent. This is a 88.71 percent decrease over earnings of…
globenewswire.com Zevra Reports Second Quarter 2026 Financial Results and Corporate Update $39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA 53% increase in total net revenue over Q2 2025 Operational execution fueled strong cash position of $260.2…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (“Zevra” or the “Company”) (NASDAQ: ZVRA). Such investors are…- benzinga.com Zevra Therapeutics Announces Publication Of "Long-Term Real-World Safety And Effectiveness Of Arimoclomol In Individuals With NPC: Outcomes From US Early Access Program Over A 4-Year Period" In Molecular Genetics And Metabolism Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced the…
- benzinga.com Canaccord Genuity Maintains Buy on Zevra Therapeutics, Lowers Price Target to $20 Canaccord Genuity analyst Sumant Kulkarni maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $29 to $20.
- benzinga.com Guggenheim Maintains Buy on Zevra Therapeutics, Lowers Price Target to $24 Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $29 to $24.
benzinga.com Ford To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Monday Wall Street analysts changed outlook on top names. See all rating changes on Benzinga's analyst ratings page for F, RIVN, TSM, ZVRA, ARWR, VZ, HBAN, GM, SAP, and CHTR.- benzinga.com BTIG Maintains Buy on Zevra Therapeutics, Lowers Price Target to $24 BTIG analyst Kambiz Yazdi maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $27 to $24.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Tenet Healthcare (NYSE:THC) stock increased by 17.3% to $233.54 during Friday's regular session. The market value of their outstanding shares is at $17.4 billion. The company's, Q2 earnings…
benzinga.com Zevra Therapeutics Stock Down — European Panel Slams Arimoclomol Bid for Niemann-Pick Type C The CHMP issues a negative opinion on Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C, prompting a re-examination request.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 28.3% to $21.53 during Friday's pre-market session. The company's market cap stands at $27.4 million. Akanda (NASDAQ:AKAN) shares…- benzinga.com Zevra Therapeutics Receives Negative Opinion From EMA CHMP On Its Marketing Authorization Application For Arimoclomol For The Treatment Of Niemann-Pick Disease Type C Under European regulatory procedures, the Company plans to request a re-examination of the CHMP opinion and submit a detailed explanation outlining the basis for the request."While the review did not…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Zevra Therapeutics, Maintains $26 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and maintains $26 price target.
- benzinga.com Zevra Therapeutics Announces Publication Of Arimoclomol In Infants With Niemann-Pick Disease Type C: Results From The Phase 2/3 Open-Label Pediatric Substudy In Molecular Genetics And Metabolism Reports Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, announced the…
benzinga.com Maxim Group Maintains Buy on Zevra Therapeutics, Raises Price Target to $35 Maxim Group analyst Jason McCarthy maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the price target from $25 to $35.- benzinga.com Guggenheim Maintains Buy on Zevra Therapeutics, Raises Price Target to $29 Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the price target from $25 to $29.
benzinga.com BTIG Reiterates Buy on Zevra Therapeutics, Raises Price Target to $27 BTIG analyst Kambiz Yazdi reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the price target from $23 to $27.
benzinga.com Canaccord Genuity Maintains Buy on Zevra Therapeutics, Raises Price Target to $29 Canaccord Genuity analyst Sumant Kulkarni maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the price target from $24 to $29.- benzinga.com Citizens Maintains Market Outperform on Zevra Therapeutics, Raises Price Target to $25 Citizens analyst Jason Butler maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Market Outperform and raises the price target from $18 to $25.
- benzinga.com Cantor Fitzgerald Maintains Overweight on Zevra Therapeutics, Raises Price Target to $34 Cantor Fitzgerald analyst Kristen Kluska maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Overweight and raises the price target from $24 to $34.
- benzinga.com Zevra Therapeutics Submits U.S. Patent For MIPLYFFA To FDA For Listing In Orange Book Publication; Patent Expires On November 19, 2041 MIPLYFFA patent submitted for Orange Book listing, with patent protection to 2041Separately filed patent term extension remains pending with the U.S. Patent and Trademark OfficeBOSTON, June 08, 2026…
- benzinga.com Guggenheim Maintains Buy on Zevra Therapeutics, Raises Price Target to $25 Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the price target from $23 to $25.